Results of a randomized Trial of Chlorambucil versus Fludarabine for patients with untreated Waldenström Macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma

Journal of Clinical Oncology

Volumn 31, Issue 3, 2013, Pages 301-307

  Leblond, Véronique ^a   Johnson, Steve ^h   Chevret, Sylvie ^b   Copplestone, Adrian ⁱ   Rule, Simon ⁱ   Tournilhac, Olivier ^c   Seymour, John Francis ^o   Patmore, Russell D ^j   Wright, David ^k   Morel, Pierre ^d   Dilhuydy, Marie Sarah ^e   Willoughby, Sara ^l   Dartigeas, Caroline ^f   Malphettes, Marion ^b   Royer, Bruno ^g   Ewings, Maeve ^h   Pratt, Guy ^m   Lejeune, Julie ^b   Nguyen Khac, Florence ^a   Choquet, Sylvain ^a   Owen, Roger G ⁿ   more..

^a SORBONNE UNIVERSITÉ   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d Hopital Schaffner   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF TOURS   (France)

^g AMIENS UNIVERSITY HOSPITAL   (France)

^h TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

ⁱ PLYMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^j HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^k MID YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^l WYE VALLEY NHS TRUST   (United Kingdom)

^m UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

ⁿ ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^o UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CHLORAMBUCIL; FLUDARABINE; IMMUNOGLOBULIN M; PENTAMIDINE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CARDIOTOXICITY; CAUSE OF DEATH; CONTROLLED STUDY; DRUG FATALITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOPHENOTYPING; INFECTION; INTENTION TO TREAT ANALYSIS; LARGE CELL LYMPHOMA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MARGINAL ZONE LYMPHOMA; MILIARY TUBERCULOSIS; MULTICENTER STUDY; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEPTICEMIA; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

AGED; ANTINEOPLASTIC AGENTS; CHLORAMBUCIL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; VIDARABINE; WALDENSTROM MACROGLOBULINEMIA;

EID: 84873340787     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.7920     Document Type: Article

References (35)

1. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
2. Swerdlow SH, Campo E, Harris NL, et al (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4). Lyon, France, International Agency for Research on Cancer (IARC), 2008
3. Owen RG, Treon SP, Al-Katib A, et al: Clinicopathological definition of Waldenstrom's macroglobulinaemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinaemia. Semin Oncol 30:110-115, 2003 (Pubitemid 36506291)
4. Thieblemont C: Non-MALT marginal zone lymphomas. Ann Oncol 19: iv70-iv73, 2008 (suppl 4)
5. Treon SP, Gertz MA, Dimopoulos M, et al: Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood 107:3442-3446, 2006
6. Dimopoulos MA, Gertz MA, Kastritis E, et al: Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 27:120-126, 2009
7. Leblond V, Ben-Othman T, Deconinck E, et al: Activity of fludarabine in previously treated Waldenström's macroglobulinemia: A report of 71 cases-Groupe Coopératif Macroglobulinémie. J Clin Oncol 16:2060-2064, 1998 (Pubitemid 28265041)
8. Lefrère F, Hermine O, Belanger C, et al: Fludarabine: An effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia 14:573-575, 2000 (Pubitemid 30195446)
9. Matutes E, Oscier D, Montalban C, et al: Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 22:487-495, 2008 (Pubitemid 351386718)
10. Leblond V, Choquet S: Fludarabine in Waldenstrom's macroglobulinemia. Semin Oncol 30:239-242, 2003 (Pubitemid 36506317)
11. Cervetti G, Galimberti S, Sordi E, et al: Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol 21:851-854, 2010
12. Peinert S, Tam CS, Prince HM, et al: Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia. Leuk Lymphoma 51:2188-2197, 2010
13. Kyle RA, Treon SP, Alexanian R, et al: Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30:116-120, 2003 (Pubitemid 36506292)
14. Weber D, Treon SP, Emmanouilides C, et al: Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30:127-131, 2003 (Pubitemid 36506294)
15. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244-1253, 1999 (Pubitemid 29162950)
16. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
17. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
18. Morel P, Monconduit M, Jacomy D, et al: Prognostic factors in Waldenström macroglobulinemia: A report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood 96:852-858, 2000 (Pubitemid 30616846)
19. Phekoo KJ, Jack RH, Davies E, et al: The incidence and survival of Waldenströ m's Macroglobulinaemia in South East England. Leuk Res 32:55-59, 2008 (Pubitemid 350103805)
20. Dhodapkar MV, Jacobson JL, Gertz MA, et al: Prognostic factors and response to fludarabine therapy in patients with Waldenströ m macroglobulinemia: Results of United States intergroup trial (Southwest Oncology Group S9003). Blood 98:41-48, 2001
21. Dhodapkar MV, Hoering A, Gertz MA, et al: Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood 113:793-796, 2009
22. Gertz MA, Rue M, Blood E, et al: Multicenter phase 2 trial of rituximab for Waldenström macroglobuliemia (WM): An Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 45:2047-2055, 2004 (Pubitemid 39232853)
23. Kalpadakis C, Pangalis GA, Dimopoulou MN, et al: Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 25:127-131, 2007 (Pubitemid 47507880)
24. Tsimberidou AM, Catovsky D, Schlette E, et al: Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 107:125-135, 2006 (Pubitemid 43941641)
25. Treon SP, Branagan AR, Ioakimidis L, et al Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 113:3673-3678, 2009
26. Tedeschi A, Benevolo G, Varettoni M, et al Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: An effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer 118:434-443, 2012
27. Weber DM, Dimopoulos MA, Delasalle K, et al: 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol 30:243-247, 2003 (Pubitemid 36506318)
28. Laszlo D, Andreola G, Rigacci L, et al: Rituxmab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: Clinical and biologic results of a phase II multicenter study. J Clin Oncol 28:2233-2238, 2010
29. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al: Primary treatment of Waldenstrom macroglobuliemia with dexamethasone, rituximab and cyclosphamide. J Clin Oncol 25:3344-3349, 2007
30. Leleu X, Tamburini J, Roccaro A, et al: Balancing risk versus benefit in the treatment of Waldenstrom's Macroglobulinemia patients with nucleoside analoguebased therapy. Clin Lymphoma Myeloma 9:71-73, 2009
31. Tam CS, Seymour JF, Prince HM, et al Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica 91:1546-1550, 2006 (Pubitemid 44739896)
32. Carney DA, Westerman DA, Tam CS, et al Therapy-related myelodysplastic syndrome and acute myeloid leukemiafollowingfludarabinecombinationchemotherapy. Leukemia 24:2056-2062, 2010
33. Smith MR, Neuberg D, Flinn IW, et al: Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: Long-term follow-up of US Intergroup Study E2997. Blood 118:3525-3527, 2011
34. Varettoni M, Tedeschi A, Arcaini L, et al: Risk of second cancers in Waldenstrom macroglobulinemia Ann Oncol 23:411415, 2012
35. Ojha RP, Thertulien R: Second malignancies among Waldenstrom macroglobulinemia patients: Small samples and sparse data. Ann Oncol 23:542-543, 2012